Nonclinical assessment of carcinogenic risk and tumor growth enhancement potential of prasugrel, a platelet-inhibiting therapeutic agent

International Journal of Toxicology

Volumn 31, Issue 4, 2012, Pages 317-325

  Buckley, Lorrene A ^a   Sanbuissho, Atsushi ^b   Starling, James J ^a   Knadler, Mary Pat ^a   Iversen, Philip W ^a   Jakubowski, Joseph A ^a  

^a ELI LILLY AND COMPANY   (United States)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

carcinogenicity; prasugrel; rodent bioassay; tumor growth

Indexed keywords

ANTITHROMBOCYTIC AGENT; CYTOCHROME P450; ENZYME; PRASUGREL; R 106583; R 138727; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIOASSAY; CANCER RISK; CARCINOGENICITY; CELL PROLIFERATION; CELL STIMULATION; CLINICAL ASSESSMENT; COLON TUMOR; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; ENZYME INDUCTION; FEMALE; GENOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER ADENOMA; LIVER CARCINOGENESIS; LIVER TUMOR; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; METABOLITE; MOUSE; NONHUMAN; PROSTATE TUMOR; RAT; SERUM; STARVATION; TUMOR CELL CULTURE; TUMOR GROWTH; TUMOR XENOGRAFT;

ADENOMA, LIVER CELL; ANIMALS; BLOOD PLATELETS; CARCINOGENS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA DAMAGE; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED ICR; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; RATS; RATS, INBRED F344; RISK FACTORS; THIOPHENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865028682     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581812445073     Document Type: Article

References (28)

1. US Food and Drug Administration. EFFIENT™ Summary Review (NDA 22-307). http://www.accessdata.fda.gov/drugsatfda-docs/nda/2009/022307s000-SumR. pdf.2009. Accessed April 20, 2012.
2. European Medicines Agency. European Public Assessment Report (EPAR) of Efient. EMEA/H/C/984. http://www.ema.europa.eu/ema/index.jsp?curl=pages/ medicines/human/medicines/000984/human-med-000756.jsp&murl=menus/medicines/ medicines.jsp&mid=WC0b01ac058001d124.2009. Accessed April 20, 2012.
3. Unger EF. Weighing benefits and risks-the FDA's review of prasugrel. N Engl J Med. 2009 ; 361 (10). 942-945
4. International conference on harmonisation guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use. S2(R1). http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/ Safety/S2-R1/Step4/S2R1-Step4.pdf2011. Accessed April 20, 2012.
5. International conference on harmonisation dose selection for carcinogenicity studies of pharmaceuticals.S1C(R2). http://www.ich.org/ fileadmin/Public-Web-Site/ICH-Products/Guidelines/Safety/S1C-R2/Step4/ S1C-R2-Guideline.pdf2008. Accessed April 20, 2012.
6. US Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry (DRAFT), Statistical Aspects of the Design, Analysis, and Interpretation of Chronic Rodent Carcinogenicity Studies of Pharmaceuticals, Subsection IV C.6. 2001. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM079272.pdfAccessed April 20, 2012.
7. Peto R, Pike MC, Day NE, et al Guidelines for Simple, Sensitive Significance Tests for Carcinogenic Effects in Long-term Animal Experiments, in Long-term and Short-term Screening Assays for Carcinogens: A Critical Appraisal. Lyon: World Health Organization ; 1980: 311-426.
8. Farid NA, McIntosh M, Garofolo F, et al. Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/ tandem mass spectrometry. Rapid Commun Mass Spectrom. 2007 ; 21 (2). 169-179 (Pubitemid 46095475)
9. Popp JA, Cattley RC Handbook of Toxicologic Pathology. Haschek WM Rousseaux CG, ed. San Diego, CA: Academic Press ; 1991: 302-303.
10. Huff JE Carcinogenesis. Waalkes MP Ward JM, ed. New York, NY: Raven Press ; 1994: 25-37.
11. Feldman D, Swarm RL, Becker J. Ultrastructural study of rat liver and liver neoplasms after long-term treatment with phenobarbital. Cancer Res. 1981 ; 41 (6). 2151-2162 (Pubitemid 11111409)
12. Whysner J, Ross PM, Williams GM. Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion. Pharmacol Ther. 1996 ; 71 (1-2). 153-191 (Pubitemid 26323295)
13. Capen CC, DeLellis RA, Yarington JT Handbook of Toxicologic Pathology. Haschek WM Rousseaux CG, ed. San Diego, CA: Academic Press ; 1991: 723-736.
14. McClain RM Mouse Liver Carcinogenesis: Mechanisms and Species Comparisons. Stevenson DE McClain RM Popp JA Slaga TJ Ward JM Pitot HC, ed. New York, NY: Wiley-Liss ; 1990: 345-365.
15. Harada T, Enomoto A, Boorman GA, Maronpot RR Pathology of the Mouse. Maronpot RR, ed. Vienna, IL: Cache River Press ; 1999: 125 140 175-126 149 176.
16. Holsapple MP, Pitot HC, Cohen SH. Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol Sci. 2006 ; 89 (1). 51-56 (Pubitemid 43013754)
17. Hoflack JC, Mueller L, Fowler S, Braendli-Baiocco A, Flint N, Kuhlmann O, Singer T, Roth A. Monitoring Cyp2b10 mRNA expression at cessation of 2-year carcinogenesis bioassay in mouse liver provides evidence for a carcinogenic mechanism devoid of human relevance: The dalcetrapib experience. Toxicol. Appl. Pharmacol. 2012 ; 259 (3). 355-365
18. White SJ, McLean AE, Howland C. Anticonvulsant drugs and cancer: a cohort study in patients with severe epilepsy. Lancet. 1979 ; 2 (8140). 458-461
19. Shirts SB, Annegers JF, Hauser WA, Kurland LT. Cancer incidence in a cohort of patients with seizure disorders. J Natl Cancer Inst. 1986 ; 77 (1). 83-87 (Pubitemid 16061786)
20. Olsen JH, Boice JD, Jensen JP, Fraumeni JF. Cancer among epileptic patients exposed to anticonvulsant drugs. J Natl Cancer Inst. 1989 ; 81 (10). 803-808 (Pubitemid 19137445)
21. Pito HC, Dragan YP Casarett & Doull's Toxicology: The Basic Science of Poisons. 8: Chemical carcinogenesis. In: Klassen, ed. Casarett & Doull's Toxicology: The Basic Science of Poisons. McGraw Hill (New York) 6th ed.; 2001. New York: McGraw Hill ; 2001 :
22. Chatterjee M, Huang Z, Zhang W, et al. Distinct platelet packaging, release, and surface expression of proangiogenic and antiangiogenic factors on different platelet stimuli. Blood. 2011 ; 117 (14). 3907-3911
23. Jurasz P, Alonso-Escolano D, Radomski MW. Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol. 2004 ; 143 (7). 819-826 (Pubitemid 39664840)
24. Van Kolen K, Slegers H. P2Y12 receptor stimulation inhibits β-adrenergic receptor-induced differentiation by reversing the cyclic AMP-dependent inhibition of protein kinase B. J Neurochem. 2004 ; 89 (2). 442-453 (Pubitemid 38495992)
25. Czajkowski R, Banachewicz W, Ilnytska O, Drobot L, Baranska J. Differential effect of P2Y1 and P2Y12 nucleotide receptors on ERK1/ERK2 and phosphatidylinositol 3-kinase signaling and cell proliferation in serum-deprived and non-starved glioma C6 cells. Br J Pharmacol. 2004 ; 141 (3). 497-507 (Pubitemid 38297012)
26. Krzeminski P, Suplat D, Czakowski R, Pomorski P, Baranska J. Expression and functional characterization of P2Y1 and P2Y12 nucleotide receptors in long-term serum-deprived glioma C6 cells. FEBS J. 2007 ; 274 (8). 1970-1982 (Pubitemid 46587997)
27. Kitadai Y, Sasaki T, Kuwai T, Nakamura T, Buicana C, Fidler I. Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. Am J Pathol. 2006 ; 169 (6). 2054-2065 (Pubitemid 351181965)
28. Medina C, Jurasz P, Santos-Martinez MJ, et al. Platelet aggregation induced by Caco-2 cells: regulation by matrix metalloproteinase-2 and adenosine diphosphate. JPET. 2006 ; 317 (2). 739-745